Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Praluent neurocognitive function study in hypercholesterolemia
2016-003189-16Phase 4Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in familial hypercholesterolemia (FH) and hypercholesterolemia comparing Praluent with Placebo (2 arms). Primary endpoint: Change in CANTAB Spatial Working Memory strategy score. Started Nov 2016; status: completed.
02
Drugs
alirocumab
03
Conditions
familial hypercholesterolemia (FH)hypercholesterolemia
Beyond the preview
Go deeper on 2016-003189-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003189-16.